Esophagus to Small Intestine

Lancet. 2022;399(10342):2200–11

Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Jr., Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicenter, randomized, double-blind, parallel-group, phase 3b trial


Background: Active-comparator trials are important to inform patient and physician choice. The authors aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn’s disease.
Methods: They conducted a randomized, double-blind, parallel-group, active-comparator, phase 3b trial (SEAVUE) at 121 hospitals or private practices in 18 countries, and included biologic-naive patients aged ≥ 18 years with moderately to severely active Crohn’s disease and a Crohn’s Disease Activity Index (CDAI) score of 220–450, who had not responded to or were intolerant to conventional therapy (or were corticosteroid-dependent) and had at least 1 ulcer of any size at baseline endoscopic evaluation. Eligible patients were randomly assigned (1:1; via an interactive web response system) to receive ustekinumab (approx. 6 mg/kg i.v. on day 0, then 90 mg s.c. once every 8 weeks) or adalimumab (160 mg on day 0, 80 mg at 2 weeks, then 40 mg once every 2 weeks, s.c.) through week 56. Study treatments were administered as monotherapy and without dose modifications. Patients, investigators, and study site personnel were masked to treatment group assignment. The primary end point was the proportion of patients who were in clinical remission (CDAI score < 150) at week 52 in the intention-to-treat population (i.e., all patients who were randomly assigned to a treatment group).
Findings: Between June 28, 2018, and December 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to receive ustekinumab (n = 191) or adalimumab (n = 195). 29 of 191 patients (15%) in the ustekinumab group and 46 of 195 (24%) in the adalimumab group discontinued study treatment before week 52. There was no significant difference between the ustekinumab and adalimumab groups in the occurrence of the primary end point; at week 52, 124 of 191 patients (65%) in the ustekinumab group versus 119 of 195 (61%) in the adalimumab group were in clinical remission (between-group difference, 4%; 95% confidence interval: -6–14; p = 0.42). Safety for both groups was consistent with previous reports. Serious infections were reported in 4 of 191 patients (2%) in the ustekinumab group and 5 of 195 (3%) in the adalimumab group. No deaths occurred through week 52 of the study.

Interpretation: Both ustekinumab and adalimumab monotherapies were highly effective in this population of biologic-naive patients, with no difference in the primary outcome between the drugs.

B.E. Sands, M.D., Professor of Medicine, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA,
E-Mail: bruce.sands@mssm.edu

DOI: 10.1016/s0140-6736(22)00688-2

Back to overview

this could be of interest:

Over-the-scope clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: A randomized controlled trial (STING-2)

Gut. 2022;71(7):1251–8

Tirzepatide once weekly for the treatment of obesity

N Engl J Med. 2022;387(3):205–16

More articles on the topic